{
    "functional_evidence_assessment": [
        {
            "variant_id": {
                "Gene": "LRRK2",
                "Protein_Change": {
                    "ref": "R",
                    "alt": "C",
                    "position": "1441"
                },
                "variant_string_id": "LRRK2 R1441C"
            },
            "functional_evidence_aim": "Pathogenic",
            "assessment_steps": [
                {
                    "step_name": "Step 1: Define the disease mechanism",
                    "extracted_paper_info": "Parkinson's disease (PD) is caused by loss of nigrostriatal dopaminergic neurons. LRRK2 is the gene responsible for autosomal - dominant PD, PARK8. The kinase activity of LRRK2 may play a key role in neurodegeneration, but its true function and mechanism of neurodegeneration from its mutations are unknown.",
                    "judgment": "Yes",
                    "reasoning": "The paper clearly states that PD is due to loss of specific neurons and LRRK2 is implicated in the disease, along with suggestions about the role of its kinase activity in neurodegeneration.",
                    "next_step_or_outcome": "Proceed to Step 2"
                },
                {
                    "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
                    "extracted_paper_info": "In vitro kinase assay with recombinant proteins was used to study LRRK2 phosphorylation of Akt1, and knockdown experiments in intact cells were also performed.",
                    "judgment": "Yes",
                    "reasoning": "The in vitro kinase assay and knockdown experiments are relevant to studying the kinase function of LRRK2, which is related to the proposed role of LRRK2 kinase activity in neurodegeneration.",
                    "next_step_or_outcome": "Proceed to Step 3"
                },
                {
                    "step_name": "Step 3: Evaluate validity of specific instances of assays - Sub - step 3a: Basic Controls and Replicates",
                    "extracted_paper_info": "The text mentions 'Stars represent statistical comparisons by one - way ANOVA (n = 3)' in the figures related to experiments with the variant, indicating multiple replicates. Wild - type LRRK2 was used as a control in the kinase assay when testing the variant's effect on Akt1 phosphorylation.",
                    "judgment": "Yes",
                    "reasoning": "Both the use of wild - type as a normal control and the mention of n = 3 replicates meet the requirements for this sub - step.",
                    "next_step_or_outcome": "Proceed to Sub - step 3c"
                },
                {
                    "step_name": "Step 3: Evaluate validity of specific instances of assays - Sub - step 3c: Variant Controls",
                    "extracted_paper_info": "The wild - type LRRK2 was used as a control when testing the phosphorylation of Akt1 by the R1441C mutant LRRK2.",
                    "judgment": "Yes",
                    "reasoning": "The use of wild - type LRRK2 as a control variant meets the criteria for this sub - step.",
                    "next_step_or_outcome": "Proceed to Step 4"
                },
                {
                    "step_name": "Step 4: Apply evidence to individual variant interpretation - Sub - step 4a: Statistical Analyses",
                    "extracted_paper_info": "The text mentions 'Stars represent statistical comparisons by one - way ANOVA (n = 3); **: p < 0.005' when comparing the phosphorylation level of Akt1 by wild - type and mutant (R1441C) LRRK2.",
                    "judgment": "Yes",
                    "reasoning": "The use of one - way ANOVA and reporting of p - values indicates sufficient statistical analysis to potentially estimate OddsPath.",
                    "next_step_or_outcome": "Proceed to Sub - step 4c"
                },
                {
                    "step_name": "Step 4: Apply evidence to individual variant interpretation - Sub - step 4c: Correlate OddsPath",
                    "extracted_paper_info": "The R1441C mutant LRRK2 exhibited significantly weaker kinase activity of Akt1 (Ser473)-phosphorylation than the wild - type LRRK2. However, no direct OddsPath value is given. But based on the significant difference in phosphorylation activity, it can be inferred that the functional evidence shows a pathogenic effect.",
                    "judgment": "PS3_moderate",
                    "reasoning": "Since the mutant shows a significant decrease in a key function (Akt1 phosphorylation) related to the disease mechanism, and assuming a moderate impact on OddsPath based on the described significant difference, the evidence strength is PS3_moderate.",
                    "next_step_or_outcome": "Final evidence strength determined"
                }
            ],
            "final_evidence_strength": {
                "type": "Pathogenic",
                "strength": "PS3_moderate"
            },
            "overall_conclusion": "The R1441C variant in LRRK2 was tested using relevant assays with proper controls and replicates. Statistical analysis showed a significant decrease in Akt1 phosphorylation by the mutant compared to wild - type. Based on this, the functional evidence strength is PS3_moderate as it shows a likely pathogenic effect on the function related to Parkinson's disease mechanism."
        },
        {
            "variant_id": {
                "Gene": "LRRK2",
                "Protein_Change": {
                    "ref": "G",
                    "alt": "S",
                    "position": "2019"
                },
                "variant_string_id": "LRRK2 G2019S"
            },
            "functional_evidence_aim": "Pathogenic",
            "assessment_steps": [
                {
                    "step_name": "Step 1: Define the disease mechanism",
                    "extracted_paper_info": "Parkinson's disease (PD) is caused by loss of nigrostriatal dopaminergic neurons. LRRK2 is the gene responsible for autosomal - dominant PD, PARK8. The kinase activity of LRRK2 may play a key role in neurodegeneration, but its true function and mechanism of neurodegeneration from its mutations are unknown.",
                    "judgment": "Yes",
                    "reasoning": "The paper clearly states that PD is due to loss of specific neurons and LRRK2 is implicated in the disease, along with suggestions about the role of its kinase activity in neurodegeneration.",
                    "next_step_or_outcome": "Proceed to Step 2"
                },
                {
                    "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
                    "extracted_paper_info": "In vitro kinase assay with recombinant proteins was used to study LRRK2 phosphorylation of Akt1, and knockdown experiments in intact cells were also performed.",
                    "judgment": "Yes",
                    "reasoning": "The in vitro kinase assay and knockdown experiments are relevant to studying the kinase function of LRRK2, which is related to the proposed role of LRRK2 kinase activity in neurodegeneration.",
                    "next_step_or_outcome": "Proceed to Step 3"
                },
                {
                    "step_name": "Step 3: Evaluate validity of specific instances of assays - Sub - step 3a: Basic Controls and Replicates",
                    "extracted_paper_info": "The text mentions 'Stars represent statistical comparisons by one - way ANOVA (n = 3)' in the figures related to experiments with the variant, indicating multiple replicates. Wild - type LRRK2 was used as a control in the kinase assay when testing the variant's effect on Akt1 phosphorylation.",
                    "judgment": "Yes",
                    "reasoning": "Both the use of wild - type as a normal control and the mention of n = 3 replicates meet the requirements for this sub - step.",
                    "next_step_or_outcome": "Proceed to Sub - step 3c"
                },
                {
                    "step_name": "Step 3: Evaluate validity of specific instances of assays - Sub - step 3c: Variant Controls",
                    "extracted_paper_info": "The wild - type LRRK2 was used as a control when testing the phosphorylation of Akt1 by the G2019S mutant LRRK2.",
                    "judgment": "Yes",
                    "reasoning": "The use of wild - type LRRK2 as a control variant meets the criteria for this sub - step.",
                    "next_step_or_outcome": "Proceed to Step 4"
                },
                {
                    "step_name": "Step 4: Apply evidence to individual variant interpretation - Sub - step 4a: Statistical Analyses",
                    "extracted_paper_info": "The text mentions 'Stars represent statistical comparisons by one - way ANOVA (n = 3); **: p < 0.005' when comparing the phosphorylation level of Akt1 by wild - type and mutant (G2019S) LRRK2.",
                    "judgment": "Yes",
                    "reasoning": "The use of one - way ANOVA and reporting of p - values indicates sufficient statistical analysis to potentially estimate OddsPath.",
                    "next_step_or_outcome": "Proceed to Sub - step 4c"
                },
                {
                    "step_name": "Step 4: Apply evidence to individual variant interpretation - Sub - step 4c: Correlate OddsPath",
                    "extracted_paper_info": "The G2019S mutant LRRK2 exhibited significantly weaker kinase activity of Akt1 (Ser473)-phosphorylation than the wild - type LRRK2. However, no direct OddsPath value is given. But based on the significant difference in phosphorylation activity, it can be inferred that the functional evidence shows a pathogenic effect.",
                    "judgment": "PS3_moderate",
                    "reasoning": "Since the mutant shows a significant decrease in a key function (Akt1 phosphorylation) related to the disease mechanism, and assuming a moderate impact on OddsPath based on the described significant difference, the evidence strength is PS3_moderate.",
                    "next_step_or_outcome": "Final evidence strength determined"
                }
            ],
            "final_evidence_strength": {
                "type": "Pathogenic",
                "strength": "PS3_moderate"
            },
            "overall_conclusion": "The G2019S variant in LRRK2 was tested using relevant assays with proper controls and replicates. Statistical analysis showed a significant decrease in Akt1 phosphorylation by the mutant compared to wild - type. Based on this, the functional evidence strength is PS3_moderate as it shows a likely pathogenic effect on the function related to Parkinson's disease mechanism."
        },
        {
            "variant_id": {
                "Gene": "LRRK2",
                "Protein_Change": {
                    "ref": "I",
                    "alt": "T",
                    "position": "2020"
                },
                "variant_string_id": "LRRK2 I2020T"
            },
            "functional_evidence_aim": "Pathogenic",
            "assessment_steps": [
                {
                    "step_name": "Step 1: Define the disease mechanism",
                    "extracted_paper_info": "Parkinson's disease (PD) is caused by loss of nigrostriatal dopaminergic neurons. LRRK2 is the gene responsible for autosomal - dominant PD, PARK8. The kinase activity of LRRK2 may play a key role in neurodegeneration, but its true function and mechanism of neurodegeneration from its mutations are unknown.",
                    "judgment": "Yes",
                    "reasoning": "The paper clearly states that PD is due to loss of specific neurons and LRRK2 is implicated in the disease, along with suggestions about the role of its kinase activity in neurodegeneration.",
                    "next_step_or_outcome": "Proceed to Step 2"
                },
                {
                    "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
                    "extracted_paper_info": "In vitro kinase assay with recombinant proteins was used to study LRRK2 phosphorylation of Akt1, and knockdown experiments in intact cells were also performed.",
                    "judgment": "Yes",
                    "reasoning": "The in vitro kinase assay and knockdown experiments are relevant to studying the kinase function of LRRK2, which is related to the proposed role of LRRK2 kinase activity in neurodegeneration.",
                    "next_step_or_outcome": "Proceed to Step 3"
                },
                {
                    "step_name": "Step 3: Evaluate validity of specific instances of assays - Sub - step 3a: Basic Controls and Replicates",
                    "extracted_paper_info": "The text mentions 'Stars represent statistical comparisons by one - way ANOVA (n = 3)' in the figures related to experiments with the variant, indicating multiple replicates. Wild - type LRRK2 was used as a control in the kinase assay when testing the variant's effect on Akt1 phosphorylation.",
                    "judgment": "Yes",
                    "reasoning": "Both the use of wild - type as a normal control and the mention of n = 3 replicates meet the requirements for this sub - step.",
                    "next_step_or_outcome": "Proceed to Sub - step 3c"
                },
                {
                    "step_name": "Step 3: Evaluate validity of specific instances of assays - Sub - step 3c: Variant Controls",
                    "extracted_paper_info": "The wild - type LRRK2 was used as a control when testing the phosphorylation of Akt1 by the I2020T mutant LRRK2.",
                    "judgment": "Yes",
                    "reasoning": "The use of wild - type LRRK2 as a control variant meets the criteria for this sub - step.",
                    "next_step_or_outcome": "Proceed to Step 4"
                },
                {
                    "step_name": "Step 4: Apply evidence to individual variant interpretation - Sub - step 4a: Statistical Analyses",
                    "extracted_paper_info": "The text mentions 'Stars represent statistical comparisons by one - way ANOVA (n = 3); **: p < 0.005' when comparing the phosphorylation level of Akt1 by wild - type and mutant (I2020T) LRRK2.",
                    "judgment": "Yes",
                    "reasoning": "The use of one - way ANOVA and reporting of p - values indicates sufficient statistical analysis to potentially estimate OddsPath.",
                    "next_step_or_outcome": "Proceed to Sub - step 4c"
                },
                {
                    "step_name": "Step 4: Apply evidence to individual variant interpretation - Sub - step 4c: Correlate OddsPath",
                    "extracted_paper_info": "The I2020T mutant LRRK2 exhibited significantly weaker kinase activity of Akt1 (Ser473)-phosphorylation than the wild - type LRRK2. However, no direct OddsPath value is given. But based on the significant difference in phosphorylation activity, it can be inferred that the functional evidence shows a pathogenic effect.",
                    "judgment": "PS3_moderate",
                    "reasoning": "Since the mutant shows a significant decrease in a key function (Akt1 phosphorylation) related to the disease mechanism, and assuming a moderate impact on OddsPath based on the described significant difference, the evidence strength is PS3_moderate.",
                    "next_step_or_outcome": "Final evidence strength determined"
                }
            ],
            "final_evidence_strength": {
                "type": "Pathogenic",
                "strength": "PS3_moderate"
            },
            "overall_conclusion": "The I2020T variant in LRRK2 was tested using relevant assays with proper controls and replicates. Statistical analysis showed a significant decrease in Akt1 phosphorylation by the mutant compared to wild - type. Based on this, the functional evidence strength is PS3_moderate as it shows a likely pathogenic effect on the function related to Parkinson's disease mechanism."
        }
    ]
}